Cancer

Mouse studies suggest dual inhibition of MCL1 and MEK could help treat KRAS-mutant adenocarcinoma. In seven patient-derived xenograft (PDX) mouse models of KRAS-mutant adenocarcinoma, the MCL1 inhibitor AMG 176 plus the MEK inhibitor Mekinist trametinib increased tumor regression compared with Mekinist alone. Next steps could include testing the safety of the inhibitor combination in the models.

Japan Tobacco Inc. and Novartis AG market Mekinist to treat melanoma and non-small cell lung cancer (NSCLC) and have the compound in preclinical through Phase II testing for other cancers...